Literature DB >> 10763916

A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies.

S F Jia1, L L Worth, E S Kleinerman.   

Abstract

The purpose of these studies was to develop a metastatic osteosarcoma nude mouse model to evaluate the in vivo efficacy of new therapeutic compounds. Human SAOS-2 osteosarcoma cells (10(6) cells) were injected i.v. into nude mice. Cells isolated from a rare pulmonary metastases 6 months later were established (SAOS-LM1) in culture and re-injected. This procedure was repeated 5 additional times to produce the SAOS-LM6 cell line. Visible pulmonary nodules were present 8 weeks following i.v. injection of 10(6) SAOS-LM6 cells as compared to 17 weeks using SAOS-LM2 cells. Microscopic SAOS-LM6 pulmonary metastases were demonstrated at 6 weeks. Administration of adriamycin on week 9 resulted in regression of macroscopic SAOS-LM6 lung tumors. The ability of the model to be used to evaluate the effectiveness of a biologic agent against microscopic disease was also verified. It was concluded that this model can assess therapeutic efficacy and therefore, may have a role in investigating the potential of novel approaches aimed at eliminating pulmonary metastatic osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10763916     DOI: 10.1023/a:1006623001465

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  20 in total

1.  Interferon-alpha enhances the sensitivity of human osteosarcoma cells to etoposide.

Authors:  S F Jia; T An; L Worth; E S Kleinerman
Journal:  J Interferon Cytokine Res       Date:  1999-06       Impact factor: 2.607

2.  Retroviral vector-mediated transfer of an antisense cyclin G1 construct inhibits osteosarcoma tumor growth in nude mice.

Authors:  D S Chen; N L Zhu; G Hung; M J Skotzko; D R Hinton; V Tolo; F L Hall; W F Anderson; E M Gordon
Journal:  Hum Gene Ther       Date:  1997-09-20       Impact factor: 5.695

3.  Selection of successive tumour lines for metastasis.

Authors:  I J Fidler
Journal:  Nat New Biol       Date:  1973-04-04

4.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity.

Authors:  M P Link; A M Goorin; A W Miser; A A Green; C B Pratt; J B Belasco; J Pritchard; J S Malpas; A R Baker; J A Kirkpatrick
Journal:  N Engl J Med       Date:  1986-06-19       Impact factor: 91.245

5.  Timing of chemotherapy and surgery in a murine osteosarcoma model.

Authors:  R S Bell; Y F Roth; M C Gebhardt; D F Bell; A E Rosenberg; H J Mankin; H D Suit
Journal:  Cancer Res       Date:  1988-10-01       Impact factor: 12.701

6.  Metastatic behavior of tumor cells isolated from primary and metastatic human colorectal carcinomas implanted into different sites in nude mice.

Authors:  R Giavazzi; D E Campbell; J M Jessup; K Cleary; I J Fidler
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

7.  Development and characterization of pediatric osteosarcoma xenografts.

Authors:  W H Meyer; J A Houghton; P J Houghton; B L Webber; E C Douglass; A T Look
Journal:  Cancer Res       Date:  1990-05-01       Impact factor: 12.701

8.  Sequential therapy with chemotherapeutic drugs and liposome-encapsulated muramyl tripeptide: determination of potential interactions between these agents.

Authors:  J J Killion; E S Kleinerman; M R Wilson; M Tanaka; I J Fidler
Journal:  Oncol Res       Date:  1992       Impact factor: 5.574

9.  The biology, pathology and immunology of a virus induced rat osteosarcoma. I. Biological behaviour and histopathology.

Authors:  A A Czitrom; F Langer; A E Gross; E P Urovitz; K P Pritzker
Journal:  Int Orthop       Date:  1980       Impact factor: 3.075

10.  Radiation-induced osteosarcoma in the rat as a model for osteosarcoma in man.

Authors:  L M Cobb
Journal:  Br J Cancer       Date:  1970-06       Impact factor: 7.640

View more
  66 in total

1.  Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma.

Authors:  Jeremy J McGuire; Niveditha Nerlakanti; Chen Hao Lo; Marilena Tauro; Thomas J Utset-Ward; Damon R Reed; Conor C Lynch
Journal:  Int J Cancer       Date:  2020-06-29       Impact factor: 7.396

2.  Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases.

Authors:  Gangxiong Huang; Ling Yu; Laurence Jn Cooper; Mario Hollomon; Helen Huls; Eugenie S Kleinerman
Journal:  Cancer Res       Date:  2011-11-10       Impact factor: 12.701

3.  Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells.

Authors:  Upal Basu-Roy; N Sumru Bayin; Kirk Rattanakorn; Eugenia Han; Dimitris G Placantonakis; Alka Mansukhani; Claudio Basilico
Journal:  Nat Commun       Date:  2015-04-02       Impact factor: 14.919

4.  Bone marrow cells participate in tumor vessel formation that supports the growth of Ewing's sarcoma in the lung.

Authors:  Zhichao Zhou; Keri Schadler Stewart; Ling Yu; Eugenie S Kleinerman
Journal:  Angiogenesis       Date:  2010-12-24       Impact factor: 9.596

5.  Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine.

Authors:  Nancy Gordon; Nadezhda V Koshkina; Shu-Fang Jia; Chand Khanna; Arnulfo Mendoza; Laura L Worth; Eugenie S Kleinerman
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

6.  Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases.

Authors:  Nadezhda V Koshkina; Krithi Rao-Bindal; Eugenie S Kleinerman
Journal:  Cancer       Date:  2011-02-01       Impact factor: 6.860

7.  The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells.

Authors:  Wei Fu; Le Ma; Baoky Chu; Xue Wang; Marilyn M Bui; Jennifer Gemmer; Soner Altiok; W Jackson Pledger
Journal:  Mol Cancer Ther       Date:  2011-04-13       Impact factor: 6.261

8.  Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis.

Authors:  Nicholas T Woods; Hirohito Yamaguchi; Francis Y Lee; Kapil N Bhalla; Hong-Gang Wang
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

9.  Osteoblastic and osteolytic human osteosarcomas can be studied with a new xenograft mouse model producing spontaneous metastases.

Authors:  Jun Yuan; Christian Ossendorf; Jan P Szatkowski; James T Bronk; Avudaiappan Maran; Michael Yaszemski; Mark E Bolander; Gobinda Sarkar; Bruno Fuchs
Journal:  Cancer Invest       Date:  2009-05       Impact factor: 2.176

10.  p27 Is a Candidate Prognostic Biomarker and Metastatic Promoter in Osteosarcoma.

Authors:  Yiting Li; Manjula Nakka; Aaron J Kelly; Ching C Lau; Mark Krailo; Donald A Barkauskas; John M Hicks; Tsz-Kwong Man
Journal:  Cancer Res       Date:  2016-04-19       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.